# Greenwich LifeSciences, Inc.: overview GLSI · Nasdaq · CIK 1799788 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/glsi.md) · [Financials](/companies/glsi/financials.md) · [Filings](/companies/glsi/filings.md) · [Insiders](/companies/glsi/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.20)](/filings/0001493152-25-023539.md) | not reported | [(0.21)](/filings/0001493152-26-027150.md) | [(0.28)](/filings/0001493152-26-037147.md) | [(0.27)](/filings/0001493152-26-026651.md) | not reported | [(0.39)](/filings/0001493152-26-027150.md) | [(0.27)](/filings/0001493152-26-037147.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.35)](/filings/0001493152-22-007377.md) | [(0.61)](/filings/0001493152-24-014625.md) | [(0.69)](/filings/0001641172-25-004819.md) | [(1.34)](/filings/0001493152-26-026651.md) | [(1.43)](/filings/0001493152-26-026651.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/glsi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $11.4m | 485,854 | | Added +51,994 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.5m | 278,190 | | Reduced −20,076 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.9m | 168,179 | | Added +12,713 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.4m | 143,086 | | Added +9,211 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.9m | 80,861 | | Added +21,950 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $1.9m | 80,228 | | Added +5,103 | | [Bank of New York Mellon Corp](/funds/1390777.md) | 2026-06-30 | $1.1m | 47,900 | | Added +1,377 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $1.1m | 45,965 | | Added +1,057 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.0m | 43,447 | | Added +13,620 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $922.7k | 39,329 | | Reduced −192 | ## Recent filings [All 278 filings](/companies/glsi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 16:30 ET | [DEF 14A](/filings/0001493152-26-048537.md) | Proxy statement, period 2026-10-26 | 0001493152-26-048537 | | 2026-08-11 | 16:30 ET | [10-Q](/filings/0001493152-26-037147.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037147 | | 2026-06-04 | 18:19 ET | [10-Q](/filings/0001493152-26-027150.md) | Quarterly report, period 2026-03-31 | 0001493152-26-027150 | | 2026-06-01 | 16:56 ET | [10-K](/filings/0001493152-26-026651.md) | Annual report, period 2025-12-31 | 0001493152-26-026651 | | 2025-12-18 | 16:30 ET | [8-K](/filings/0001493152-25-028361.md) | 5.07 Shareholder vote results | 0001493152-25-028361 | | 2025-11-14 | 16:30 ET | [10-Q](/filings/0001493152-25-023539.md) | Quarterly report, period 2025-09-30 | 0001493152-25-023539 | | 2025-11-03 | 17:07 ET | [DEF 14A](/filings/0001493152-25-020623.md) | Proxy statement, period 2025-11-03 | 0001493152-25-020623 | | 2025-08-14 | 16:30 ET | [10-Q](/filings/0001641172-25-024066.md) | Quarterly report, period 2025-06-30 | 0001641172-25-024066 | | 2025-07-24 | 16:30 ET | [8-K](/filings/0001641172-25-020843.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001641172-25-020843 | | 2025-05-20 | 16:30 ET | [10-Q](/filings/0001641172-25-011731.md) | Quarterly report, period 2025-03-31 | 0001641172-25-011731 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-026651.md), filed Jun 1, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1799788 - Tickers: GLSI - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:53 ET. No prices; not investment advice.